Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild-to-Moderate COVID-19 Clear all
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Not listed Phase 2 Interventional

Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting

NCT04840459
View directory record Official record
Conditions
Covid19
Interventions
BAMLANIVIMAB, CASIRIVIMAB, IMDEVIMAB
Biological
Lead sponsor
Sohail Rao
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Edinburg, Texas • Rio Grande City, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional

Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress

NCT04800120
View directory record Official record
Conditions
Covid19
Interventions
Hyperbaric Oxygen Therapy
Other
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Taunton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 1, 2023 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients

NCT05941793
View directory record Official record
Conditions
Mild to Moderate COVID-19
Interventions
MBS-COV, Placebo
Drug
Lead sponsor
Oneness Biotech Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Recruiting Phase 1Phase 2 Interventional

SARS-CoV-2 CTLS for Mild to Moderate COVID-19 Disease

NCT04896606
View directory record Official record
Conditions
Covid19
Interventions
Standard of Care, SARS-CoV2-CTLS
Other · Biological
Lead sponsor
New York Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
4
States / cities
Valhalla, New York • Columbus, Ohio • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

NCT04419025
View directory record Official record
Conditions
COVID, Sars-CoV2, SARS-Associated Coronavirus as Cause of Disease Classified Elsewhere, Oxidative Stress
Interventions
N-acetylcysteine
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Cambridge, Massachusetts • Everett, Massachusetts • Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19

NCT04779879
View directory record Official record
Conditions
Covid19
Interventions
Sotrovimab (Gen1), Sotrovimab (Gen2)
Biological
Lead sponsor
Vir Biotechnology, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Anniston, Alabama • Bakersfield, California • Northridge, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional Results available

CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients

NCT04734873
View directory record Official record
Conditions
Covid-19
Interventions
CPI-006 2 mg/kg + SOC, CPI-006 1 mg/kg + SOC, Placebo + SOC
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
13
States / cities
Chula Vista, California • El Centro, California • La Mesa, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2022 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 1Phase 2 Interventional

JINZHEN for Treatment of Mild to Moderate COVID-19

NCT05092503
View directory record Official record
Conditions
COVID-19
Interventions
JINZHEN Granules for Oral Solution, Placebo
Drug
Lead sponsor
Lianyungang Kanion Group, Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Canyon Country, California • Hialeah Gardens, Florida • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04701658
View directory record Official record
Conditions
COVID-19
Interventions
Bamlanivimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

NCT04966013
View directory record Official record
Conditions
COVID19
Interventions
RD-X19, Sham
Device
Lead sponsor
EmitBio Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Clearwater, Florida • Miami, Florida • Kalamazoo, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Completed No phase listed Observational

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

NCT04681079
View directory record Official record
Conditions
COVID-19
Interventions
albuterol sulfate (MDI), albuterol sulfate (nebulizer)
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.

NCT04880109
View directory record Official record
Conditions
COVID-19
Interventions
APX-115, Placebo
Drug
Lead sponsor
Aptabio Therapeutics, Inc.
Individual
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Little Rock, Arkansas • Annapolis, Maryland • Wyoming, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 3 Interventional Results available

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

NCT04870606
View directory record Official record
Conditions
Efficacy and Safety
Interventions
Proxalutamide (GT0918), Placebo
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Long Beach, California • Sandy Springs, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19

NCT04305457
View directory record Official record
Conditions
Coronavirus Infections, Pneumonia, Viral, Acute Respiratory Distress Syndrome
Interventions
Nitric Oxide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Shreveport, Louisiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04551898
View directory record Official record
Conditions
Covid19
Interventions
BGB-DXP593, Placebo
Drug
Lead sponsor
BeiGene
Industry
Eligibility
18 Years to 65 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
DeLand, Florida • Hollywood, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacokinetics, Pharmacodynamics, and Safety of Single-dose Sotrovimab in High-risk Pediatric Participants With Mild to Moderate COVID-19

NCT05124210
View directory record Official record
Conditions
COVID-19
Interventions
Sotrovimab
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
0 Days to 18 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Cullman, Alabama • Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 1 Interventional

A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19

NCT05386472
View directory record Official record
Conditions
COVID-19
Interventions
nirmatrelvir, ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Birmingham, Alabama • Cutler Bay, Florida • DeBary, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Not applicable Interventional Results available

Phase I/II Safety, Dose Finding & Antiviral Activity of RD-X19 in Mild/Moderate Outpatient COVID-19

NCT04662671
View directory record Official record
Conditions
COVID19
Interventions
RD-X19
Device
Lead sponsor
EmitBio Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Miami, Florida • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

Sargramostim Use in COVID-19 to Recover Patient Health

NCT04707664
View directory record Official record
Conditions
Covid19, SARS-CoV Infection
Interventions
Sargramostim, Placebo
Drug
Lead sponsor
Partner Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Canoga Park, California + 30 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2023 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

NCT04656691
View directory record Official record
Conditions
Covid19
Interventions
bamlanivimab
Drug
Lead sponsor
Daniel Griffin
Industry
Eligibility
65 Years and older
Enrollment
139 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Minnetonka, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2022 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional

Bucillamine in Treatment of Patients With COVID-19

NCT04504734
View directory record Official record
Conditions
Covid19
Interventions
Bucillamine, Placebo
Drug
Lead sponsor
Revive Therapeutics, Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
713 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
46
States / cities
Cullman, Alabama • Huntsville, Alabama • Phoenix, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Jul 22, 2026, 4:56 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
INOpulse, Placebo
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Jul 22, 2026, 4:56 PM EDT
Completed Phase 2 Interventional Results available

A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness

NCT04634409
View directory record Official record
Conditions
COVID-19
Interventions
Bamlanivimab, Etesevimab, Placebo, VIR-7831, Bebtelovimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,755 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
127
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Jul 22, 2026, 4:56 PM EDT